|
robert stroud, PHDDr. Robert Stroud is a Professor of Biochemistry and Biophysics at University of California, San Francisco (UCSF), where he studies the molecular mechanisms of certain key biological processes, as well as signal transduction between processes at the level of protein structure, dynamics, and mechanism. He began his studies at Cambridge University in 1961, studying physics and mathematics, where he first began to study X-ray crystallography and protein structures and continued with his PhD work in physics in the laboratory of J.D. Bernal, where Rosalind Franklin had previously discovered the double helical structure of DNA. He was one of the first scientists to decode a crystal structure (of tubercidin). He completed his postdoctoral studies at the California Institute of Technology before becoming an assistant professor at Caltech. In 1976, he joined UCSF's faculty and was one of the founders of their structural biology program. He continues to work towards improving drug design and our understanding of biological molecules. He is part of the National Academy of Sciences, Royal Society of Medicine, and has received numerous honors and awards for his pioneering work in X-ray crystallography, biophysics, and structural biology.
Read more: https://www.pnas.org/content/103/14/5256 |
|
JEFF KARP, PHDDr. Jeff Karp is a Professor of Medicine at Brigham and Women’s Hospital, Harvard Medical School, Principal Faculty at the Harvard Stem Cell Institute, and an affiliate faculty at the Broad Institute and at the Harvard-MIT Division of Health Sciences and Technology (where he teaches to HST and MIT-Sloan business school students). His work spans the fields of drug delivery, medical devices, stem cell therapeutics, and tissue adhesives. He He has published >100 peer-reviewed papers (with >16,500 citations), has given >275 national and international invited lectures, and has >100 issued or pending national/international patents. Several technologies developed in his lab have formed the foundation for multiple products on the market and currently under development and for the launch of six companies that have raised over $180 Million in funding including Skintifique (a skincare company), Gecko Biomedical (a tissue adhesive company), Alivio Therapeutics (an inflammation targeting company), Frequency Therapeutics (a regenerative medicine company), Molecular Infusions (a cannabinoid company), and Landsdowne Labs (a child safety company). In addition to his research goals, Karp is dedicated to the career development of next generation bioengineers to work at the forefront of regenerative medicine.
Read more: https://hsci.harvard.edu/people/jeffrey-karp-phd |
|
AGNIESZKA CZECHOWICZ, MD, PHDDr. Agnieszka Czechowicz is an Assistant Professor at Stanford University. She is a pediatric hematologist/oncologist, and sub-focuses on pediatric stem cell transplantation. She also runs a translational research group focusing on understanding hematopoeitic stem cells and how they interact with their microenvironments. Agnieszka completed her residency in Pediatrics at Boston Children's Hospital, and pursued fellowship training at the Dana Farber Cancer Institute and Lucile Packard Children's Hospital. She consulted for Third Rock ventures and incubated numerous companies including Editas, Magenta Therapeutics, and Global Blood Therapeutics, and currently advises GV. She graduated from Stanford University School of Medicine with a MD/PhD in developmental biology in the Medical Scientist Training Program, in record breaking time. She also earned an undergraduate degree with honors from Stanford University, in biological sciences and received the Firestone medal for her outstanding senior thesis. Agnieszka is an author on numerous publications, including a first author on a paper published in the November 2007 issue of Science which shows a possible way to eliminate the toxicity of bone marrow transplantation (BMT), a discovery that could expand the applications of BMT to include cures for most blood diseases, as well as autoimmune diseases like diabetes. She is in the process of translating these discoveries and developing them into new therapies for patients.
Read more: https://profiles.stanford.edu/agnieszka-czechowicz |